Work

A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer

Year: 2015

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-015-0241-7

Authors: Analia Azaro, Jordi Rodon, Antonio Calles, Irene Braña, Manuel Hidalgo, Pedro P. Lopez-Casas, Manuel Munoz, Paul Westwood, Joel Miller, Brian A. Moser, Ute Ohnmacht, William Bumgardner, Karim A. Benhadji, Emiliano Calvo

Institutions: Universitat Autònoma de Barcelona, Vall d'Hebron Hospital Universitari, Spanish National Cancer Research Centre, Eli Lilly (United States)

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Eli Lilly and Company

OpenAlex ID: W2018320891

FWCI: 1.448

Cites: 36

Cited by: 30

Related to: 10